Literature DB >> 11004103

Utility of predictive equations for estimating the prevalence and incidence of primary open angle glaucoma in the UK.

D C Minassian1, A Reidy, M Coffey, A Minassian.   

Abstract

AIMS: To assess the Tuck-Crick and the Quigley-Vitale predictive regression equations against fresh independent real world data for estimating the prevalence of primary open angle glaucoma (POAG) in the UK. To apply the equations to the elderly population of England and Wales, for which there is sample survey data on glaucoma, and demographic data.
METHODS: Directly measured actual prevalence of POAG in a population sample of 1530 people was compared with the predicted prevalence derived by applying the Tuck-Crick and the Quigley-Vitale equations to the sample data. The two equations were applied to the demographic data of the population to project POAG prevalence and to derive 5 year cumulative incidence for the elderly population. These were compared with estimates derived from the local survey data.
RESULTS: The actual directly measured prevalence of POAG in the local sample was 3.01%. The Tuck-Crick estimate was 2. 74% (difference 0.27%), and the Quigley-Vitale was 3.50% (difference -0.49%). The three methods-projection from local survey data, Tuck-Crick, and Quigley-Vitale-gave point estimates of 2.85% (228 526 cases), 2.71% (217 375 cases), and 3.50% (280 364 cases) respectively for the prevalence of POAG in the elderly population of England and Wales (8 008 705 people aged 65 or older). Calculation of incidence from age specific prevalence gave the following results: the numbers of new cases of POAG expected (5 year cumulative incidence) in the elderly population were 71 146 and 94 485 for methods 2 and 3 respectively.
CONCLUSIONS: The Tuck-Crick predictive equation performed well when applied to fresh (independent) actual data from a local sample survey using a particular definition for POAG, and its usefulness for estimation of prevalence of POAG in England and Wales has been demonstrated. The work on development of predictive equations has been very promising and further refinements could be made when more fresh survey data become available.

Entities:  

Mesh:

Year:  2000        PMID: 11004103      PMCID: PMC1723266          DOI: 10.1136/bjo.84.10.1159

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  The age distribution of primary open angle glaucoma.

Authors:  M W Tuck; R P Crick
Journal:  Ophthalmic Epidemiol       Date:  1998-12       Impact factor: 1.648

2.  Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study.

Authors:  A Reidy; D C Minassian; G Vafidis; J Joseph; S Farrow; J Wu; P Desai; A Connolly
Journal:  BMJ       Date:  1998-05-30

3.  Models of open-angle glaucoma prevalence and incidence in the United States.

Authors:  H A Quigley; S Vitale
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

4.  Underprivileged areas: validation and distribution of scores.

Authors:  B Jarman
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-08

5.  Estimating incidence from age-specific prevalence in glaucoma.

Authors:  M C Leske; F Ederer; M Podgor
Journal:  Am J Epidemiol       Date:  1981-05       Impact factor: 4.897

  5 in total
  10 in total

Review 1.  Primary open angle glaucoma. The need for a consensus case definition.

Authors:  M Kroese; H Burton
Journal:  J Epidemiol Community Health       Date:  2003-09       Impact factor: 3.710

2.  Glaucoma prescribing trends in England 2000 to 2012.

Authors:  A J Connor; S G Fraser
Journal:  Eye (Lond)       Date:  2014-05-23       Impact factor: 3.775

Review 3.  The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.

Authors:  Jean-François Rouland; Gilles Berdeaux; Antoine Lafuma
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003.

Authors:  C G Owen; I M Carey; S De Wilde; P H Whincup; R Wormald; D G Cook
Journal:  Br J Ophthalmol       Date:  2006-07       Impact factor: 4.638

Review 5.  Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension.

Authors:  James E Frampton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data.

Authors:  Aimee Teo Broman; Harry A Quigley; Sheila K West; Joanne Katz; Beatriz Munoz; Karen Bandeen-Roche; James M Tielsch; David S Friedman; Jonathan Crowston; Hugh R Taylor; Rohit Varma; M Cristina Leske; Boel Bengtsson; Anders Heijl; Mingguang He; Paul J Foster
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

7.  The prevalence and incidence of glaucoma in Norway 2004-2018: A nationwide population-based study.

Authors:  Jon Klokk Slettedal; Valgerður Dóra Traustadóttir; Leiv Sandvik; Amund Ringvold
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

Review 8.  Advanced glaucoma at diagnosis: current perspectives.

Authors:  Alan Kastner; Anthony J King
Journal:  Eye (Lond)       Date:  2019-11-18       Impact factor: 3.775

9.  Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial.

Authors:  Victoria Vickerstaff; Gareth Ambler; Catey Bunce; Wen Xing; Gus Gazzard
Journal:  Trials       Date:  2015-11-11       Impact factor: 2.279

10.  12-month clinical outcomes of combined phacoemulsification and ab interno trabeculectomy for open-angle glaucoma in the United Kingdom.

Authors:  Ejaz Ansari; Deva Loganathan
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.